The government estimates that the revision will result in a total annual saving of more than €287 million. Photo credit: Prostooleh/Freepik
Spain’s Ministry of Health has announced a sweeping review of the prices of more than 17,000 medicines currently available on the national pharmaceutical market. The move, aimed at ensuring fair pricing and reducing public spending, is expected to generate savings exceeding €287 million per year for the national health system.
The review forms part of the government’s broader strategy to strengthen the sustainability of Spain’s public healthcare system, improve access to essential treatments, and ensure that pharmaceutical companies align with updated market conditions.
A Comprehensive Review Across the Health System
Updating outdated prices to reflect market realities
The price reassessment will affect both prescription and hospital-use medicines financed through Spain’s National Health System (SNS). According to the Ministry of Health, the process includes an exhaustive analysis of existing products, ranging from common treatments for chronic conditions to specialised hospital drugs.
Officials emphasised that the initiative is not focused on limiting access or availability, but rather on updating outdated pricing structures that have not kept pace with market realities. The review covers thousands of active substances and branded products whose prices were originally set years ago, some of which no longer reflect the real cost of production or distribution.
By modernising these prices, the Ministry hopes to optimise public resources and redirect savings into areas of growing need, such as digital health innovation, research, and new therapeutic treatments.
Ensuring Fair Prices and Patient Access
Balancing efficiency with equitable healthcare
The Spanish Agency for Medicines and Health Products (AEMPS) has been tasked with conducting the technical review and collaborating with regional health authorities. The process will take into account clinical effectiveness, therapeutic value, and market competition, ensuring that reductions do not compromise patient access or quality standards.
According to the Health Ministry, the measure will affect the financing conditions of around 17,000 pharmaceutical presentations currently included in Spain’s official catalogue of reimbursable medicines.
While most changes are expected to result in moderate price adjustments, a small proportion may see more significant reductions, particularly in areas where cheaper generic or bio-similar alternatives exist. The goal, the ministry stated, is to achieve “greater efficiency without undermining access or innovation.”
Savings to Reinforce the Public Health System
Strengthening the SNS and controlling rising costs
The government estimates that the revision will result in a total annual saving of more than €287 million, benefiting both regional health services and patients. These savings will contribute to budgetary stability within the SNS and help offset rising healthcare costs linked to Spain’s ageing population and the increasing use of advanced therapies.
Experts in the sector have noted that Spain’s pharmaceutical spending has steadily increased over the past decade, reaching over €13 billion in 2024. The Ministry’s reform could help curb spending growth while maintaining equitable access to essential drugs.
Health Minister Mónica García underscored that the review is “a key step in ensuring that every euro invested in healthcare delivers maximum social and medical benefit.” She added that the ministry remains committed to collaborating with pharmaceutical companies and professional associations to implement the changes smoothly.
Reactions from the Healthcare and Pharmaceutical Sectors
Medical support and industry caution
The response from the healthcare sector has been largely positive, with medical associations welcoming the initiative as a means to reduce inefficiencies and strengthen public funding. However, representatives from the pharmaceutical industry have urged the ministry to proceed carefully, warning that sharp price cuts could affect profitability and investment in new medicines.
The Spanish Federation of Pharmaceutical Industries (Farmaindustria) has requested transparency and consultation throughout the process, arguing that stable pricing frameworks are crucial for maintaining supply and innovation.
Looking Ahead
Gradual implementation and long-term sustainability
The implementation of the price review will take place progressively over the coming months, with new pricing updates to be reflected in Spain’s Official Gazette (BOE) once approved.
If successfully executed, the reform could serve as a model for other European countries seeking to balance innovation with financial sustainability in their health systems.
Ultimately, the initiative reinforces Spain’s commitment to a public, universal, and efficient healthcare system, ensuring that patients continue to receive high-quality treatments at fair and sustainable costs.